Catherine Mezzacappa remembers the moment she realized a simple number could change the course of a patient’s life. At the VA hospital in New Haven, Connecticut, she and her team were searching for a better way to spot liver disease before it became deadly. For years, doctors struggled to predict which patients with steatotic liver disease (SLD) — a condition where fat builds up in the liver — would go on to develop cirrhosis, a life-threatening scarring of the liver. Now, after analyzing data from more than 850,000 veterans, they’ve found a tool that works better than the rest: the SAFE score.
Liver disease often hides in plain sight. People can live for years without symptoms, only to be diagnosed when serious damage has already occurred. Early detection is key, but not all risk scores are equally useful. That’s why Mezzacappa and her colleagues at Yale School of Medicine put nine different scoring systems to the test, using real-world data from the U.S. Veterans Affairs health system. Their goal was simple: find the score that best predicts who will develop cirrhosis or liver cancer within 10 years.
The results were clear. The SAFE score — short for steatosis-associated fibrosis estimator — outperformed the others in predicting cirrhosis. Among 853,131 patients with SLD, 3.96% developed cirrhosis over a decade. The SAFE score identified these high-risk patients more accurately than any other tool. At a threshold of 29.5, it flagged individuals with a 2.5% 10-year risk of cirrhosis, meaning 1.9 more cases were correctly caught per 100 people classified as at risk. It also performed well in predicting hepatocellular carcinoma (HCC), the most common type of liver cancer, though the risk for that was much lower — just 0.35% of patients over 10 years.
What makes the SAFE score so powerful is that it’s based on routine blood tests and patient history — no expensive scans or invasive procedures. It uses factors like age, platelet count, and liver enzyme levels to calculate risk. That makes it practical for clinics everywhere, especially in underserved areas where advanced diagnostics are scarce.
This isn’t just about numbers — it’s about giving doctors a clearer roadmap. With a reliable score, they can monitor high-risk patients more closely, recommend lifestyle changes, or start treatments earlier. For patients, it means a better chance at stopping liver disease before it’s too late.
As the team writes, “This comparative validation study highlights the importance of assessing test performance at relevant thresholds for clinical practice.” In plain terms: not all tools are created equal, and choosing the right one saves lives. With the SAFE score now proven at scale, a new standard in liver care may be within reach.